Benign Prostatic Hyperplasia (BPH) Treatment Devices Market Trends, Technological Advancements, and Growth Opportunities
Benign Prostatic Hyperplasia (BPH) refers to an enlarged prostate
gland. The prostate gland surrounds the urethra, the tube that carries urine
from the bladder out of the body. Enlargement of prostate gland leads to
blockage in urethra, thus causing problems during urination. It involves
glandular and stromal epithelial hyperplasia, which occurs in the peri-urethral
transition zone surrounding the urethra. BPH is common in aging men, and about
half of all men between the age of 51 to 60 years suffer from BPH. The global
BPH treatment devices market is expected to increase in the forecast period
(2017-2023) due to increasing aging population, rising prevalence of BPH,
increasing awareness about BPH procedures and surge in adoption of minimally invasive
procedures.
On the basis
of end user, the BPH treatment devices market is segmented into hospitals,
specialty clinics and ambulatory surgery centers. Hospitals accounted for the
largest share of the BPH treatment devices market in 2016, followed by
specialty clinics and ambulatory surgery centers. of the largest share of
hospitals as an end user is mainly attributable to large number of
hospitalization of patients suffering from urological disorder in hospitals and
early adoption of new devices in hospitals.
Growing
aging population, rising prevalence of BPH, rise in the awareness about various
BPH disorders and surge in the adoption of minimally invasive procedures are
the some of the major factors driving the growth of the BPH treatment devices
market.
Request
to Get the Sample Pages at:
Many
initiatives are also being taken to increase the awareness about symptoms and
treatment options available for BPH. For instance, in North America, every
year, September is observed as National Prostate Health Month by health
experts, health advocates, and individuals concerned with the prostate health
of men. The main purpose of designating a whole month for prostate health is to
create awareness, educate people about the risk factors and symptoms of
prostate related diseases and other factors. Various such factors are driving
the growth of BPH treatment devices market.
Asia Pacific
is expected to witness fastest growth in the forecast period due to high
incidence of urological disorders, rising incidence of benign prostatic
hyperplasia in developing countries, and increased investment from key players
in emerging economies.
The
companies are launching various products and are expanding in various
geographies to gain a larger share in the BPH treatment devices market.
In March
2017, NeoTract announced the expansion of its minimally invasive UroLift System
to be available in Ireland. The expansion of the product in Ireland was
supported by Vhi group, a private health insurance firm.
In June
2017, Olympus Corporation announced the expansion of its PLASMA Resection in
Africa that provides clinical benefits and cost saving procedure, in comparison
to monopolar transurethral resection of the prostate (TURP).
In September
2016, NeoTract, Inc. (NeoTract) announced that the company has received the de
novo approval from USFDA for its UroLife system for prostate implant.
Comments
Post a Comment